Pretreatment hydronephrosis associated with inferior overall survival in patients with muscle-invasive bladder cancerHydronephrosis linked to worse survival in bladder cancer patients

This meta-analysis evaluated the prognostic impact of pretreatment hydronephrosis on clinical outcomes in adults diagnosed with muscle-invasive bladder cancer (MIBC). The study population consisted of 8586 patients who were managed using various radiotherapy-based bladder preservation strategies, including radiotherapy alone, concurrent chemoradiotherapy, and trimodality therapy. The primary objective was to determine if the presence of hydronephrosis before treatment influenced overall survival across these different therapeutic modalities.

The analysis examined several specific treatment cohorts to ensure the consistency of the finding. For patients receiving chemoradiotherapy, pretreatment hydronephrosis was associated with inferior overall survival (HR 1.74; 95% CI 1.30-2.32; I^2 34%). In the radiotherapy alone cohort, a similar trend was observed with an HR of 1.65 (95% CI 0.38-7.19; I^2 0%). Furthermore, patients receiving trimodality therapy also showed inferior overall survival when hydronephrosis was present (HR 1.64; 95% CI 1.25-2.14; I^2 39.6%). The aggregate data for all treatment modalities combined showed a significant association with inferior overall survival (HR 1.65; 95% CI 1.43-1.91; I^2 29.8%).

Secondary outcomes further supported the role of hydronephrosis as a negative prognostic indicator. The study reported that pretreatment hydronephrosis was associated with worse cancer-specific survival (HR 2.00; 95% CI 1.68-2.37; I^2 8.9%). Additionally, patients with this condition demonstrated inferior disease-free survival (HR 1.83; 95% CI 1.12-3.01; I^2 48.7%), progression-free survival (HR 1.59; 95% CI 1.02-2.49; I^2 0%), and metastasis-free survival (HR 1.56; 95% CI 1.32-1.84; I^2 0%).

Regarding safety and tolerability, the meta-analysis did not report specific data on adverse events, serious adverse events, or treatment discontinuations. However, the consistency of the findings across different radiation-based protocols suggests that hydronephrosis is a stable prognostic marker regardless of the specific intensity or combination of the primary treatment.

When compared to historical benchmarks in bladder cancer management, these results reinforce the importance of identifying baseline anatomical and physiological complications. While previous literature has established various risk factors for MIBC, this meta-analysis specifically highlights hydronephrosis as a robust, treatment-independent factor. The consistency across radiotherapy alone, chemoradiotherapy, and trimodality therapy suggests that the impact of hydronephrosis is not mitigated by the addition of chemotherapy or additional modalities.

Methodological limitations included an overall risk of bias across the included studies that was predominantly moderate. Because this is a meta-analysis of observational data regarding a clinical feature, it does not establish a direct causal link between hydronephrosis and mortality; rather, it identifies a significant association.

Clinically, these results suggest that pretreatment hydronephrosis can be utilized as a reliable prognostic indicator in the management of MIBC patients undergoing bladder-preserving therapies. Patients presenting with this condition may require closer monitoring or more intensive follow-up due to the significantly higher risk of poorer survival outcomes. Questions remain regarding the specific physiological mechanisms by which hydronephrosis contributes to these inferior outcomes and whether identifying it early can trigger specific clinical interventions to improve prognosis.